Arginine Therapy for Treatment of Pain in Children with Sickle Cell Disease (STArT)

← Back to all studies

Arginine Therapy for Treatment of Pain in Children with Sickle Cell Disease (STArT)

Health Categories: Hematology (Sickle Cell)
Health Impacts Domain: —

Summary

This is a pivotal phase 3 clinical trial using arginine as a novel treatment of pain in children with SCD. Pain in sickle cell disease (SCD) is the leading cause of hospitalizations and ED visits for children with SCD. Arginine has properties that may improve blood flow during these acute occlusion of blood vessels.

Key Publications

Related Media

—

Study Details

Long Name
Sickle Cell Disease Treatment with Arginine Therapy Trial
Short Name
STArT
Principal Investigator(s)
—
PECARN Node
—

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of the Emergency Medical Services for Children Data Center award totaling $3,200,000 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.